PROF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Profound Medical Corp (PROF) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The upcoming clinical CAPTAIN data presentation, strong revenue growth, and positive analyst sentiment provide a compelling case for investment. Despite the lack of recent trading signals and neutral insider/hedge fund activity, the stock's current price of $6.44 offers a reasonable entry point given its $12 price target and potential catalysts.
The MACD is positive at 0.125, indicating bullish momentum, though it is contracting. The RSI is neutral at 58.589, and moving averages are converging, suggesting no strong trend. Key support is at $5.853, and resistance levels are at $6.777 and $7.063, with the current price at $6.44 sitting near the pivot point of $6.315.
Upcoming clinical CAPTAIN data presentation at the European Association of Urology, which is considered a significant event for prostate cancer treatment.
Strong revenue growth of 43.13% YoY in Q4
Analyst maintains a Buy rating with a $12 price target, indicating significant upside potential.
Gross margin dropped by 5.86% YoY to 66.77%, indicating some pressure on profitability.
No recent news or significant insider/hedge fund activity to support immediate momentum.
In Q4 2025, revenue increased by 43.13% YoY to $5,977,000, net income improved by 65.25% YoY to -$8,175,000, and EPS rose by 42.11% YoY to -$0.27. However, gross margin declined by 5.86% YoY to 66.77%.
Lake Street analyst Ben Haynor maintains a Buy rating with a $12 price target, citing the upcoming CAPTAIN data presentation as a major overlooked catalyst. The analyst believes the current enterprise value of $140M is undervalued.
